Abstract
Therapeutic liposomes with an average diameter of 100 nm based on natural phospholipids (phosphatidylcholine and phosphatidylinositol) containing palmitoyl or oleoyl derivatives of the antimitotic agent combretastatin A-4 were constructed. The cytotoxicity of liposomes with the oleoyl derivative in the human breast cancer cell culture turned out to be only three times lower than that of combretastatin A-4, thus indicating the probability of facile intracellular hydrolysis of the prodrug. To achieve selective drug delivery to the tumor tissue in vivo, the diglyceride conjugate of the tetrasaccharide ligand of selectins, viz., Sialyl-Lewis X (SiaLeX, 2 mol.%) was incorporated into the liposomes. The SiaLeX-equipped liposomes loaded with the lipophilic prodrug showed a reliable inhibition of tumor growth on the model of spontaneous breast cancer in mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
